Puma forecasts $202M-$206M in 2026 NERLYNX net product revenue while planning alisertib dose escalation and new Lung2 trial
PUMA BIOTECHNOLOGY INC · PHARMACEUTICAL PREPARATIONS · Now $7.12
-9.1% in 7d after detection
Post-detection moves
1h
—
1d
-4.7%
3d
-4.3%
7d
-9.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS